VYNE Therapeutics Inc

What they do

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) is a clinical-stage biopharmaceutical company developing therapies for autoimmune thyroid diseases. Its lead candidate, YB-101 (also known as GenSci098), is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR), intended to block autoantibody-induced receptor activation. The company has exclusive worldwide rights to a library of BET inhibitors, though its current focus is on advancing YB-101.

Revenue drivers

• Collaboration and license revenue — The company generated minimal revenue, primarily from collaboration or license agreements, with annual revenue ranging from $424,000 in 2023 to $570,000 in 2025.
• No approved products — As a clinical-stage company, the company has no commercial products, and revenue is not a meaningful driver of financial performance.

Recent performance

Yarrow Bioscience, Inc. reported annual revenue of $570,000 for 2025, up from $501,000 in 2024, but net losses remained substantial at $26.5 million in 2025. Diluted EPS for 2025 was -$0.62, and operating cash flow was -$33.1 million. In the quarters ending June 30, 2026, revenue was $97,000, and the company held $22.9 million in cash with no long-term debt as of that date. The company completed the merger with Yarrow on July 27, 2026, which brought a cash infusion from a $100 million Series A financing and a $100 million pre-closing financing, but also declared a special cash dividend of $17.3 million to pre-merger shareholders.

Strategy

The company's stated strategy is to focus on advancing YB-101 for Graves' disease and to explore a clinical development plan for thyroid eye disease. Following the merger, the Combined Company will evaluate opportunities for its legacy BET inhibitor assets (repibresib and VYN202), which may include sale, license, or other monetization. Management implemented cost reductions to extend cash runway and is pursuing regulatory approval to lift the clinical hold on VYN202's Phase 1b trial.

Risks

• Merger integration and execution — The merger with Yarrow was completed, but integration risks and the company's ability to execute on YB-101 development remain.
• Clinical and regulatory failure — YB-101 is in clinical development, and there is no guarantee it will be safe, effective, or gain regulatory approval.
• Cash burn and funding needs — The company's operating cash flow was negative $33.1 million in 2025, and ongoing losses require additional financing to fund operations.
• Reliance on third-party partnerships — The company relies on licensed intellectual property from Tay Therapeutics and potential monetization transactions for legacy assets, which may not yield expected value.

Outlook

Management expects the Combined Company to prioritize YB-101 development for Graves' disease and thyroid eye disease. They may continue to evaluate monetization of repibresib and VYN202. The company's cash position and cost reductions are intended to extend the runway, but future financing may be required to support clinical trials.